CME/CE

Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates of comorbidities such as diabetes and chronic kidney disease. Despite advances in medical science, gaps persist in the identification, diagnosis, and management of heart failure among healthcare providers, particularly in the cardiology and primary care settings.

This accredited microlearning program highlights key topics in HF in video episodes that are 7-10 minutes each. Each microlearning features peer-to-peer interviews or panel discussions with leading experts in the following episodes: (1) Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression; (2) Partnering with Patients: Building Effective Communication and Support in HF Care; (3) A Practical Guide to Prescribing in HF; (4) HF Management for Patients with Comorbid Conditions; (5) Level Up Your Skills: Tailoring Management of HF.

Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates of comorbidities such as diabetes and chronic kidney disease. Despite advances in medical science, gaps persist in the identification, diagnosis, and management of heart failure among healthcare providers, particularly in the cardiology and primary care settings.

This accredited microlearning program highlights key topics in HF in video episodes that are 7-10 minutes each. Each microlearning features peer-to-peer interviews or panel discussions with leading experts in the following episodes: (1) Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression; (2) Partnering with Patients: Building Effective Communication and Support in HF Care; (3) A Practical Guide to Prescribing in HF; (4) HF Management for Patients with Comorbid Conditions; (5) Level Up Your Skills: Tailoring Management of HF.

The treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC) that has progressed on EGFR TKI therapy remains a clinical challenge, as traditional therapies have yielded only modest results. However, recent findings show that targeting HER3 can produce dramatically improved clinical outcomes. Data are rapidly emerging from late-phase trials evaluating HER3-directed antibody-drug conjugate therapies, and it is thus crucial for community-based oncologists and interprofessional care team members to be aware of these findings so they can be prepared to integrate these therapies into practice once they are available. In this activity, expert faculty in the field of NSCLC will evaluate recent data supporting the use of HER3-directed ADCs in the treatment of locally advanced and metastatic EGFR-mutated NSCLC that has progressed on EGFR TKI therapy, optimal management strategies for treatment-emergent adverse events related to these therapies, and the potential role of these agents in the current treatment paradigm. Faculty will also discuss best practices for a successful multidisciplinary approach and for optimized shared decision-making with the patient. Finally, case discussions will conclude the program to reinforce key learnings from the didactic section of the activity.

This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.

This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.

This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.

This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.

This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.

This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.

This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.